Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

M Ruggeri; Rolli FR; Kondili LA; C Nappi; Americo Cicchetti

doi:10.1080/14737167.2019.1537784

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

M Ruggeri
, Rolli FR^*
, Kondili LA
, C Nappi
, Americo Cicchetti

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

2 Citazioni (Scopus)

Abstract

E

Lingua originale	Inglese
pagine (da-a)	363-374
Numero di pagine	12
Rivista	Expert Review of Pharmacoeconomics and Outcomes Research
Volume	2019
Numero di pubblicazione	19
DOI	https://doi.org/10.1080/14737167.2019.1537784
Stato di pubblicazione	Pubblicato - 2019

All Science Journal Classification (ASJC) codes

Politiche della Salute
Farmacologia (medica)

Keywords

Cost effectiveness

Accesso al documento

10.1080/14737167.2019.1537784

Altri file e collegamenti

Cita questo

@article{c7aac6bf813145ad807292365df053a8,

title = "Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .",

abstract = "E",

keywords = "Cost effectiveness, Cost effectiveness",

author = "M Ruggeri and Rolli FR and Kondili LA and C Nappi and Americo Cicchetti",

year = "2019",

doi = "10.1080/14737167.2019.1537784",

language = "English",

volume = "2019",

pages = "363--374",

journal = "Expert Review of Pharmacoeconomics and Outcomes Research",

issn = "1473-7167",

publisher = "Taylor and Francis Ltd.",

number = "19",

}

TY - JOUR

T1 - Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

AU - Ruggeri, M

AU - FR, Rolli

AU - LA, Kondili

AU - Nappi, C

AU - Cicchetti, Americo

PY - 2019

Y1 - 2019

N2 - E

AB - E

KW - Cost effectiveness

UR - https://publicatt.unicatt.it/handle/10807/135548

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85055751580&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85055751580&origin=inward

U2 - 10.1080/14737167.2019.1537784

DO - 10.1080/14737167.2019.1537784

M3 - Article

SN - 1473-7167

VL - 2019

SP - 363

EP - 374

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

IS - 19

ER -

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo